Trp53 Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network

Gang Guo1, Luis Marrero2, Paulo Rodriguez1,2, Luis Del Valle1,3, Augusto Ochoa1, and Yan Cui1,2

Abstract

Inactivation of the tumor suppressor p53 through somatic mutations, observed in 50% of human cancers, is one of the leading causes of tumorigenesis. Clinical and experimental evidence also reveals that p53 mutations sometimes occur in tumor-associated fibroblasts, which correlate with an increased rate of metastases and poor prognosis, suggesting that p53 dysfunction in the tumor microenvironment (TME) favors tumor establishment and progression. To understand the impact of p53 inactivation in the TME in tumor progression, we compared the growth of subcutaneously inoculated B16F1 melanoma in p53null and wild-type (WT) mice. Interestingly, tumor growth in p53null mice was greatly accelerated, correlating with marked increases in CD11b+Gr-1+ myeloid-derived suppressor cells (MDSC), FoxP3+ regulatory T cells, and a loss of effector function, compared with those in WT mice. This augmented immunotolerant TME in p53null mice was associated with a marked expansion of a specialized stromal network in the tumor and spleen. These stromal cells expressed markers of fibroblastic reticular cells of lymphoid organs and were readily expanded in culture from p53null, but not WT, mice. They produced high levels of inflammatory cytokines/chemokines and immunosuppressive molecules, thereby enhancing MDSC differentiation. Furthermore, they significantly accelerated tumor progression in WT mice when co-injected with B16F1. Together, our results show that tumor-stroma interaction in hosts with dysfunctional p53 exacerbates immunosuppression by expanding the lymphoid-like stromal network that enhances MDSC differentiation and tumor progression. Cancer Res; 73(6): 1668–75. ©2012 AACR.

Introduction

The tumor suppressor p53 (Trp53, p53) inhibits tumorigenesis by inducing apoptosis and senescence of aberrant cells (1–3). Trp53 somatic mutations, observed in about 50% of human cancers and some autoimmune pathologic tissues, are major causes of tumorigenesis (1–4). Besides p53 mutations, inactivation of the p53 pathway happens under various physiologic and pathologic conditions, including viral infection, oncogene activation, and aging (1–3). Furthermore, p53 inactivation also occurs in other components of the tumor microenvironment (TME), including cancer-associated fibroblasts (CAF), which is associated with an increased rate of metastases and poor prognosis (5, 6). The TME, a complex cellular and molecular network of immune cells, stromal cells, extracellular matrix, and cytokines/chemokines, is crucial in immunomodulation that impacts tumor development, progression, and metastases (7–9). Studies by our laboratory and others showed that innate and adaptive immunities in p53null hosts are skewed toward proinflammation (10, 11). However, it is largely unexplored whether p53 inactivation in the TME alters the immunologic milieu, which exacerbates tumor progression.

Here, we hypothesized that p53 inactivation in the TME favors tumor establishment and progression. By using B16F1 melanoma, which maintains functional p53, we showed that their growth in p53null mice upon subcutaneously (s.c.) inoculation was greatly accelerated, associated with an expansion of the lymphoid-like stromal network, compared with that in wild-type (WT) mice. The p53null stroma promoted tumor progression by expressing proinflammatory cytokines/chemokines, arginase I, and inducible nitric oxide synthase (iNOS) and by augmenting the accumulation of myeloid-derived suppressor cells (MDSC).

Materials and Methods

Mice

Trp53null (B6.129S2-Trp53tm1tyj/J) and C57BL/6 mice, purchased from the Jackson Laboratories, were maintained under specific pathogen-free conditions in the Louisiana State University Health Sciences Center (LSUHSC) animal care facility following approved LSUHSC-Institutional Animal Care and Use Committee protocols.

Tumor inoculation

B16F1, purchased from American Type Culture Collection, was maintained in Dulbecco’s Modified Eagle’s Medium.
5 days. The CD45–DMEM with 10% FBS for 3 analyzed via intracellular staining 24 hours postinjection adherent cells was enriched by depletion of CD11b transcription was conducted with 1 Real-time reverse transcriptase-PCR WT mice.

Histology and fluorescent immunohistochemistry Hematoxylin and eosin stain histology and immunohistochemistry (IHC) were conducted following standard protocols and viewed by a licensed pathologist. Antibody dilutions for IHC were: ER-TR7 (5 µg/mL), Lyve-1 (5 µg/mL), α-smooth muscle actin (1 µg/mL, Abcam), Gp38 (5 µg/mL), CD31 (5 µg/mL), CD11b (1 µg/mL, Biologend), and Alexa Fluor-labeled secondary antibodies (2 µg/mL, Invitrogen). Vasculature and stroma quantification was conducted using Slidebook software (Intelligent Imaging Innovations).

Flow cytometry All antibodies were purchased from BD Biosciences unless otherwise specified. Tumors were cut into 1–2 mm² pieces and digested with liberase (0.5 wu/mL, Roche) and DNase I (100 µg/mL, Sigma) in DMEM at 37°C for 30 minutes. MDSCs were enriched using EasySep mouse CD11b positive selection kits (Stemcell Technologies). Regulatory T cells (Treg) were analyzed as CD4+CD25+Foxp3+ (ebioscence) cells. The effector cell function was determined via intracellular cytokine staining following standard protocols. Fluorescence-activated cell sorting acquisition was conducted using a FACSCalibur and analyzed using FlowJo (Tree Star Inc.).

Splenic stromal cell isolation and expansion Splenocytes, cut and digested with liberase and DNase I at 37°C for 30 minutes, were subsequently cultured at 5 × 10⁶/mL in DMEM with 10% FBS for 3–5 days. The CD45+ population from adherent cells was enriched by depletion of CD11b+cells to >95% CD45− and was passaged twice a week. Their responses to B16F1-soluble factors were evaluated after a 6-hour exposure to B16F1-conditioned medium (50%). Their effects on tumor growth were evaluated by injection of 1 × 10⁵ splenic stromal cell (SPSC) alone or mixed with 2 × 10⁶ B16F1 s.c. to WT mice.

Real-time reverse transcriptase-PCR Total RNA was harvested using Qiagen RNeasy Kits. Reverse transcription was conducted with 1 µg total RNA followed by real-time PCR using PrimeTime qPCR primers (Integrated DNA Technologies) and a BioRad CFX96 (BioRad Life Science Research).

Bone marrow-derived MDSCs Bone marrow-derived MDSCs (BM-MDSC) were cultured in DMEM containing 10% FBS, 100 ng/mL granulocyte colony-stimulating factor (G-CSF), and 10 ng/mL interleukin (IL)-6 (PeproTech) at 1 × 10⁶/mL with or without SPSCs for 4 days.

5-Bromodeoxyuridine labeling Tumor-bearing mice were injected intraperitoneally with 1 mg of bromodeoxyuridine (BrdUrd). BrdUrd− cells were analyzed via intracellular staining 24 hours postinjection (BD Biosciences). Cultured BM-MDSCs were labeled with 10 µmol/L BrdUrd for 2 hours.

Multiplex cytokine assays Mouse serum was analyzed using the Millipore Mouse Cytokine/Chemokine-Premixed kit (MPXMCYTO70KPMX32) using Bio-Plex Manager (Bio-Rad Laboratories).

Statistical analysis The differences between genotypes and/or treatments were analyzed via 2-tailed Student t tests using SigmaPlot (Systat Software Inc.). Statistical significance was set at P < 0.05.

Results and Discussion Tp53null hosts augment tolerogenic TME and promote tumor progression Previous studies suggest that p53 inactivation enhances inflammation (10–12). To investigate whether p53null-mediated inflammation promotes tumor progression, we compared B16F1 progression in WT and p53null mice. As expected, B16F1 progressed more rapidly in p53null mice (Fig. 1A), associated with significant alterations in tumor-infiltrating leukocytes (CD45+TILs), a 50% reduction in TIL-CD8, and a reciprocal increase in CD11b+ myeloid cells, compared with those in WT mice (Fig. 1B). These were in agreement with IHC results (Supplementary Fig. S1). Furthermore, IFN-γ- and IL-17A-producing effectors in p53null-TILs were markedly suppressed despite a comparable percentage of TIL-CD4 and TNF-α-producing cells between p53null and WT mice (Fig. 1B–D). It is noteworthy that the exacerbated immunotolerance in p53null mice was more profound in the TME, because the frequencies of effectors and Tregs in the spleen of WT and p53null mice were comparable (Supplementary Fig. S2). These results suggest that p53 inactivation in hosts TME favors tumor progression by augmenting immunotolerance.

The accelerated tumor progression in p53null hosts is associated with an enhanced MDSC accumulation and expansion of lymphoid-like stromal network within the TME The CD11b+ population usually comprises heterogeneous myeloid cells, including CD11b+Gr-1+ MDSCs, dendritic cells, granulocytes, and macrophages (13). Further analyses of B16F1-TILs CD11b+ cells in WT and p53null mice showed that they were predominately MDSCs (TIL-MDSC) with comparable compositions of heterogeneous Ly6Ghi Ly6Chi monocytes (M)-MDSCs and Ly6Ghi Ly6Chi monocytic (M)-MDSCs (Fig. 2A and Supplementary Fig. S3A). Nevertheless, the absolute number of TIL-MDSCs and total TIL-MDSCs in p53null mice was significantly higher than that in WT mice (Fig. 2A). Functional analyses indicated that on a per cell basis, p53null-TIL-MDSC showed a similar capacity in suppressing the proliferation of activated T cells to WT TIL-MDSC (Supplementary Fig. S3B), implying that the augmented immunosuppression in p53null mice mainly results from their increased MDSC number. In vivo BrdUrd labeling of proliferating cells showed that BrdUrd−
TIL-MDSCs, but not TIL-CD11b^+Gr-1^- cells, almost doubled in tumor-bearing p53^null mice compared with those in WT counterparts (Fig. 2B), suggesting that p53 inactivation in the TME enhances the proliferation of MDSCs.

Recent studies suggest that MDSCs in the TME augment angiogenesis. Pathologic examination of tumor specimens revealed that tumors growing in p53^null, but not WT, mice appeared to be organized into isle-like structures with
marked increases in vasculatures (Fig. 2C). Emerging evidence suggests that during inflammation and tumor progression, lymphatic vasculatures and fibroblasts form a network reminiscent of the specialized stroma of secondary lymphoid organs (14, 15). Analyses of B16F1 tumors showed marked increases in both blood endothelial cells (CD45⁺/CO2CD31⁺GP38⁺/CO2Lyve-1⁺) and lymphatic endothelial cells (LEC; CD45⁺/CO2CD31⁺GP38⁺Lyve-1⁺), associated with......
increased TIL-CD11b+ cells in p53null hosts (Fig. 2D). More strikingly, a fibroblast network, reminiscent of fibroblastic reticular cells (FRC) that are ER-TR7α-SMAα-smooth muscle actinGP38α-gastrointestinal stromal tumors (GIST) (15), was expanded extensively in tumors from p53null mice compared with that from WT mice (Fig. 2D). These results suggest that p53 inactivation in the TME provides a permissive environment for angiogenesis and expansion of FRC-like network.

**B16F1 establishment in p53null hosts promotes systemic increases in proinflammatory cytokines, MDSCs, and stromal network in the spleen**

To understand how p53null TME encourages MDSC proliferation/accumulation, we first examined host cytokine milieu as it provides essential signals for MDSC development (13). In WT tumor-bearing mice compared with nontumor-bearing mice, serum G-CSF and CXCL1 (keratinocyte chemoattractant) levels doubled and tripled, respectively (Fig. 3A). Likewise, serum G-CSF, CXCL1, and IL-6 in p53null tumor-bearing mice showed a 4- to 10-fold increases compared with nontumor-bearing mice (Fig. 3A). Further analysis of splenic MDSCs (SP-MDSC) in tumor-bearing WT and p53null mice showed that both M-MDSCs and G-MDSCs in the spleen of p53null mice were significantly higher because of their marked increases in proliferation, that is, BrdUrd+ SP-MDSCs (Fig. 3B and C). Further immunohistochemical analyses also confirmed a significant expansion of the FRC network in the spleen of tumor-bearing p53null mice compared with nontumor-bearing p53null mice and tumor-bearing WT mice (Fig. 3D). Thus, our results suggest that tumor-stroma interaction in the TME lacking functional p53 promotes inflammation, accumulation of MDSCs, and expansion of the FRC network.
Figure 4. p53null splenic fibroblastic stroma enhances MDSC differentiation and accelerates tumor progression in WT mice. A, a representative image (×400) and phenotypic analyses of CD45SPSC from tumor-bearing p53null mice. Open lines indicate isotype controls. B, BM-MDSCs were differentiated in a 4-day culture with G-CSF and IL-6 with or without SPSCs. Their relative efficiency was normalized against that of WT BM-MDSCs without SPSCs, which was set as 100%. Proliferating (BrdUrd⁺) BM-MDSCs were examined on day 4 (n = 3). *, significant difference (P < 0.05) between groups with and without SPSCs; †, significant difference between WT and p53null BM-MDSCs. C, proinflammatory molecule expression in p53null SPSCs compared with those in MEF, as well as their alterations upon a 6-hour exposure to B16F1-conditioned medium, was determined via real-time RT-PCR (n = 3–5). D, the tumor size in WT mice that received 2 × 10⁵ B16F1 or 2 × 10⁵ B16F1 admixed with 1 × 10⁵ p53null SPSCs was compared (n = 5). *, significant difference (P < 0.05).
**Trp53null splenic fibroblastic stroma enhances MDSC differentiation and markedly accelerates tumor progression in WT mice**

Given the essential role of lymphoid FRC network in immune regulation (15) and the role of SP stroma in inducing regulatory dendritic cells (16), we postulated that p53null stroma augments MDSC development. Interestingly, splenic CD45− stromal cells, termed SPSCs, from tumor-bearing p53null, but not WT, mice were readily expanded in culture. Further analyses showed that SPSCs, differing from mouse embryonic fibroblasts (MEF; Supplementary Fig. S4), were CD106+CD54+GP38+ Sca−1lo−/− lymphoid FRC-like cells (Fig. 4A). To assess the function of SPSCs in promoting MDSC differentiation under a cytokine milieu mimicking B16F1 tumorbearing mice (Fig. 3A), we tested BM-MDSC differentiation in G-CSF + IL-6. Unlike G-CSF + GM-CSF (granulocyte macrophage colony-stimulating factor; ref. 17), which predominantly induced M-MDSCs (Supplementary Fig. S5), G-CSF + IL-6 supported the differentiation of heterogeneous M-MDSCs and G-MDSCs, resembling the composition of TIM-MDSCs (Fig. 2A and Supplementary Fig. S3A). In the absence of SPSCs, comparable number of BM-MDSCs was derived from the bone marrow of WT and p53null cells (Fig. 4B). Strikingly, p53null SPSCs enhanced BM-MDSC differentiation of WT and p53null cells by 60% and 100%, respectively, mainly by enhancing their proliferation (Fig. 4B and Supplementary Fig. S6).

Further analyses of the cytokine/chemokine profile of p53null SPSCs via quantitative real-time RT-PCR showed that they expressed higher levels of proinflammatory cytokines/chemokines and immunosuppressive mediators, including IL-6, IL-10, CCL3, CCL21, Arg1, and iNOS, compared with p53null MEF (Fig. 4C). Moreover, exposure of SPSCs to B16F1 conditioned medium further enhanced the expression of CXCL12, CCL3, and IL-10 (Fig. 4C). To confirm that p53null stroma hastens tumor progression, we injected p53null SPSCs either alone or mixed with B16F1 to WT mice and showed that coinjection of SPSCs with B16F1 substantially accelerated tumor growth as early as day 8 postinjection (Fig. 4D). These results strongly suggest that the lymphoid-like stroma in p53null hosts is immunosuppressive and that tumor-stroma interaction exacerbates immunosuppression, augments MDSC development, and accelerates tumor progression.

Taken together, this study shows that p53 inactivation in the TME promotes immunosuppression and tumor progression by expanding the lymphoid-like stromal network. The crucial role of the TME in tumor initiation and progression has been increasingly appreciated (7–9, 13). However, the immunologic consequence of p53 inactivation in the TME involving tumor-stroma interaction has been unexplored. Early studies suggest that p53 inactivation in CAFs enhances tumor progression via paracrine effects of CXCL12 (18). Our observed high-level CXCL12 expression in p53null SPSCs agrees with this notion. More importantly, our results further show that the p53null lymphoid-like stromal network skews the TME toward proinflammation via various inflammatory cytokines/chemokines and immunosuppressive molecules. Specifically, we postulate that the elevated G-CSF, IL-6, and IL-10 in circulation and/or the TME of p53null hosts provide crucial differentiation and survival signals for MDSCs and Tregs, respectively, while the increased expression of CXCL1, CCL3, and CCL21 plays a vital role in recruiting the immunosuppressive populations to the TME (9, 13, 19, 20). In addition, iNOS and Arg1 in the TME further augment the function of those immunosuppressors (9, 13). CXCL1, produced by melanomas or stroma, is a protumor chemokine either directly stimulates tumor via paracrine effect or indirectly via proinflammation-mediated recruitment of MDSCs (19, 20). Indeed, we detected a low level expression of CXCL1 in B16F1, which is further enhanced by tumor-stroma or tumor-immune cell interaction in the p53null TME. Therefore, the strong inflammation and resulted immunosuppressive effectors within the TME in p53null hosts are likely a result of concerted multidimensional interactions involving tumor, stroma, and immune cells.

The p53null mice used in this study best resemble those individuals with Li-Fraumeni syndrome (2). However, the immunologic mechanism revealed in this study by p53 inactivation/dysfunction in the TME enhances tumor progression should have broad clinical implications, because p53 inactivation occurs frequently during physiologic and pathologic processes via various mechanisms, including the activation of oncogenes and viral proteins, in addition to somatic mutations (1–3, 5, 6).

In summary, this is the first study that elucidates the underlying mechanism by which p53 inactivation immunomodulates the TME. These results underscore the importance and function of p53 in maintaining proper immunologic microenvironment to suppress tumorigenesis and provide valuable information for novel therapeutics by targeting p53 activity in the stroma/TME.

**Disclosure of Potential Conflicts of Interest**
No potential conflicts of interest were disclosed.

**Authors’ Contributions**
Conception and design: G. Guo, P.C. Rodriguez, A.C. Ochoa, Y. Cui
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): G. Guo, L. Marrero, L.D. Valle, Y. Cui
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): G. Guo, L. Marrero, L.D. Valle, A.C. Ochoa, Y. Cui
Writing, review, and/or revision of the manuscript: P.C. Rodriguez, A.C. Ochoa, Y. Cui
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): G. Guo, L. Marrero, Y. Cui
Study supervision: Y. Cui

**Acknowledgments**
The authors thank Drs. Tomoko Iwakuma, Daizou Sakamura, Suresh Alahari, Krzysztof Reiss, and Wanguo Liu for critical discussions.

**Grant Support**
Supported by LCRC and NIH grants CA112065 to Y. Cui and P20RR021970 to A. Ochoa.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 1, 2012; revised November 30, 2012; accepted December 17, 2012; published OnlineFirst January 14, 2013.
References

Trp53 Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-3810

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/01/14/0008-5472.CAN-12-3810.DC1

Cited articles
This article cites 20 articles, 6 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/6/1668.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/73/6/1668.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/73/6/1668.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.